Ted Karkus - ProPhase Labs Chairman and CEO

PRPH Stock  USD 6.26  0.03  0.48%   

Chairman

Mr. Ted William Karkus is a Chairman of the Board, Chief Executive Officer of the Company. Mr. KARKUS was the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was formerly the managing member of Forrester Financial, LLC, a management consulting firm founded by Mr. Karkus in 2001. Forrester Financial LLC provided a wide range of services to emerginggrowth companies, including the structuring and raising of working capital as well as assisting management in developing operational, marketing and financial strategies. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over 1.4 billion. Mr. Karkus has twentyfive years of experience in securities and capital markets including two years with Fahnestock Co. Inc. a fullservice brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981. Mr. Karkus brings extensive financial structuring as well as operational and marketing strategy experience to our Board, including successful restructuring and turnaround scenarios in the pharmaceutical industry. These skills, as well as Mr. Karkus experience as our Chairman and Chief Executive Officer, along with his deep knowledge of and genuine interest in our Company, management skills and business savvy, and his performance as a Board member of the Company, led the Board to conclude that he should be nominated to serve another term as a director. since 2009.
Age 65
Tenure 15 years
Professional MarksMBA
Address 711 Stewart Avenue, Garden City, NY, United States, 11530
Phone215 345 0919
Webhttps://www.prophaselabs.com
Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981.

Ted Karkus Latest Insider Activity

Tracking and analyzing the buying and selling activities of Ted Karkus against ProPhase Labs stock is an integral part of due diligence when investing in ProPhase Labs. Ted Karkus insider activity provides valuable insight into whether ProPhase Labs is net buyers or sellers over its current business cycle. Note, ProPhase Labs insiders must abide by specific rules, including filing SEC forms every time they buy or sell ProPhase Labs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

ProPhase Labs Management Efficiency

The company has return on total asset (ROA) of (0.1505) % which means that it has lost $0.1505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.297) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.29. The ProPhase Labs' current Return On Assets is estimated to increase to -0.17. As of now, ProPhase Labs' Other Current Assets are decreasing as compared to previous years. The ProPhase Labs' current Intangible Assets is estimated to increase to about 10.2 M, while Total Current Assets are projected to decrease to under 27.5 M.
The company currently holds 23.38 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. ProPhase Labs has a current ratio of 4.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ProPhase Labs until it has trouble settling it off, either with new capital or with free cash flow. So, ProPhase Labs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ProPhase Labs sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ProPhase to invest in growth at high rates of return. When we think about ProPhase Labs' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

CHAIRMAN Age

Michael EsqMustang Bio
58
Noubar AfeyanSeres Therapeutics
55
Mats Olsson23Andme Holding Co
63
Boon KohAgilent Technologies
70
Giovanni Lettieri23Andme Holding Co
58
Vernon LoboEquillium
48
Keith GollustMadrigal Pharmaceuticals
72
Daniel BradburyEquillium
63
James CullenAgilent Technologies
72
Roger PomerantzSeres Therapeutics
60
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people. ProPhase Labs (PRPH) is traded on NASDAQ Exchange in USA. It is located in 711 Stewart Avenue, Garden City, NY, United States, 11530 and employs 15 people. ProPhase Labs is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

ProPhase Labs Leadership Team

Elected by the shareholders, the ProPhase Labs' board of directors comprises two types of representatives: ProPhase Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProPhase. The board's role is to monitor ProPhase Labs' management team and ensure that shareholders' interests are well served. ProPhase Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProPhase Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Billy White, Consultant
Robert Cuddihy, CFO, COO, Principal Accounting Officer and Executive VP
Mark Burnett, Independent Director
Ted Karkus, Chairman and CEO
Sergio Miralles, Executive Diagnostics
Jason Karkus, President Diagnostics
James McCubbin, Compliance Officer, Independent Director and Member of Audit Committee
Mark Leventhal, Independent Director
Louis Gleckel, Independent Director
Robert Morse, Principal Controller
Kamal Obbad, Senior Genomics
Monica Brady, Principal Financial Officer & Principal Accounting Officer
Jed Latkin, Chief Department
Alice Lioi, EVP BioPharma
Jason Barr, Director

ProPhase Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProPhase Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as ProPhase Labs using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for ProPhase Stock analysis

When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is ProPhase Labs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.95)
Earnings Share
(0.63)
Revenue Per Share
2.629
Quarterly Revenue Growth
(0.80)
Return On Assets
(0.15)
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.